A Multicenter Phase I/II Clinical Study on Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection (CT120) for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Multicenter Phase I/II Clinical Study on Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection (CT120) for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma is a PHASE1 clinical asset sponsored by Nanjing IASO Biotechnology Co., Ltd. in B-cell Non-Hodgkin's Lymphoma. SEO and diligence focus: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: B-cell Non-Hodgkin's Lymphoma
Modality: small molecule
Target: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
Sponsor: Nanjing IASO Biotechnology Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
View original source fields
Condition raw: B-cell Non-Hodgkin's Lymphoma
Condition normalized: B-cell Non-Hodgkin's Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
Target normalized: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection